A Suspected COVID-19-associated Myocarditis Case Mimicking Life-threatening STEMI: a Shark Fin Appearance
Versions
- 2021-03-27 (2)
- 2021-03-27 (1)
Downloads
Some cases of myocarditis have been reported associated to Covid-19. The presence of proinflammatory response from immune cells suggested occurs by binding to membrane protein ACE-2 leading to myocardial damage. Our hospital got a refferal from a non-PCI-capable hospital with a 51-years-old woman chest pain and progressive heavy breath with history of fever two days ago. She was diagnosed with anterior STEMI and cardiogenic shock on vassopressors. Her electrocardiogram showed shark fin appearance suggesting life-threatening STEMI. Her rapid test for covid-19 are non-reactive for both IgM and IgG. Her NCCT-thorax showed ground glass opacity in both lungs. Her laboratories finding showed elevated inflammatory markers and elevated cardiac biomarker. We took her naso-oro-pharingeal swab in the same day and process her with emergency PCI. Surprisingly, her angiography showed normal coronary artery without any significant stenosis. From There was no SARS-CoV-2 detected. In myocarditis, patient can mimick the same symptoms as STEMI such as chest pain and heavy breath with elevated cardiac biomarker, but the electrocardiogram usually shows widespread concave ST-elevation with PR-segment depression. Shark fin appearance is usually seen in life-threatening STEMI. In our patient, the NCCT-thorax showed GGO suggested Covid-19 involvement. But, the first swab was negative for SARS-CoV-2. Unfortunately, the patient was discharged without doctor's consent, so we can not process the second swab and echocardiography to evaluate the function of myocardium. We still can not confirmed this case if it is true myocarditis-associated covid-19 and how was the involvement of the myocardium creating a shark fin mimicking life-threatening STEMI.
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation report - 44. Published March 4, 2020. Accessed April 15, 2020. <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200304-sitrep44-covid-19.pdf?sfvrsn=783b4c9d_2>
Wu Z., McGoogan JM. 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;2019:2-5.
Caforio AL., Pankuweit S., Arbustini E., Basso C., Gimeno"Blanes J., Felix SB., et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current stats of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34:2636–2648, 2648a"2648d.
Siripantong B., Nazarian S., Muser D. Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020. Volume 17, Issue 9, 1463-1471. https://doi.org/10.1016/j.hrthm.2020.05.001
Pirzada A., Mokhtar AT., Moeller AD. Review, COVID-19 and myocarditis: What do we know so far. CJC Open 2; 2020. 278-285.
Oleszak F., Maryniak A., Botti A., Abrahim C., Sali fu MO., Youssef M, et al. Myocarditis Associated with COVID-19. Am J Med Case Rep. 2020; 8(12): 498–502. doi:1.12691/ajmcr-8-12-19.
Inciardi RM., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., et al. Cardiac Involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1-6.
Zeng JH., Liu YX., Yuan J., Wang FX., Wu WB., Li JX., et al. First case of COVID 19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;1-5.
Doyen D., Moceri P., Ducreux D., Dellamonica J. 2020. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395(10235):1516.
Nicol M., Cacoub L., Baudet M., Nahmani Y., Cacoub P., Cohen A.et al. 2020. Delayed acute myocarditis and COVID"19"related multisystem inflammatory syndrome. ESC Heart Failure (2020) DOI: 10.1002/ehf2.13047.
Trogen B., Gonzalez FJ., Shust GF. COVID-19-associated myocarditis in an adolescent. Pediatr Infect Dis J. 2020;39(8):e204-5.
Sardari A., Tabarsi P., Borhany H., Mohiaddin R., Houshmand G. 2020. Myocarditis detected after COVID-19 recovery. Eur Heart J Cardiovasc Imaging. 2020;jeaa166.
Yuan WF., Tang X., Zhao XX. 2020. An ‘asymptomatic' driver with COVID-19: atypical suspected myocarditis by SARS-CoV-2. Cardiovasc Diagn Ther. 2020;10(2):242-3.
Cizgici AY., Zencirkiran AH., Yildiz M. COVID-19 myopericarditis: it should be kept in mind in today's conditions. Am J Emerg Med. 2020;38(7):1547.e5-1547.e6.
Asif T., Ali Z. Transient ST segment elevation in two patients with COVID-19 and a normal transthoracic echocardiogram. Eur J Case Rep Intern Med. 2020;7(5):001672.
Irabien-Ortiz A., Carreras-Mora J., Sionis A., Pamies J., Montiel J., Tauron M. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol (Engl Ed). 2020;73(6):503-4.
Çınar T., Hayıroğlu MI., Çiçek V., Uzun M., Orhan AL. 2020. COVID-19 and acute myocarditis: current literature review and diagnostic challenges. REV ASSOC MED BRAS 2020; 66(SUPPL 2):48-54. http://dx.doi.org/10.1590/1806-9282.66.S2.48
Zhou R. Does SARS"CoV"2 cause viral myocarditis in COVID"19 patients? Eur Heart J 2020; 41: ehaa392.
Peretto G, Sala S, Caforio AL. 2020. Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus"associated myocardial involvement. Eur Heart J 2020; 41: ehaa396.
Kim IC., Kim JY., Kim HA., Han S. COVID"19"related myocarditis in a 21"year"old female patient. Eur Heart J 2020; 41: 1859.
Tavazzi G., Pellegrini C., Maurelli M., Belliato M., Sciutti F., Bottazzi A., et al. 2020. Myocardial localization of coronavirus in COVID"19 cardiogenic shock. Eur J Heart Fail 2020; 22: 911–915.
Sinha, M. K., Dasgupta, D., & Lyons, J. P. (2004). "Tombstone” ST segment elevation of acute myocardial infarction. Postgraduate Medical Journal, 80, 276.
Copyright (c) 2021 Ratna Mariana Tamba, Andika Sitepu
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Cardiovascular and Cardiometabolic Journal (CCJ) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
-
Authors who publish with Cardiovascular and Cardiometabolic Journal (CCJ) agree to the following terms:
-
The journal allows the author to hold the copyright of the article without restrictions.
-
The journal allows the author(s) to retain publishing rights without restrictions.
-
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA).